TruScreen completes NZ$2.9m rights issue, 15% oversubscribed
What's the deal? TruScreenDealroom has a profile for this one. Try Dealroom → Group, a dual-listed medical device maker, has finalised a NZ$2.9 million (about US$1.6 million) renounceable rights issue that came in substantially oversubscribed. The company received applications for 171,653,080 shares — 15% above the 149,464,986 shares on offer. Shares were priced at NZ$0.013 each, and combined with an earlier placement the raise totals just over NZ$4 million.
Why now? TruScreen opened the raise on 21 May 2026 and closed it in mid-June 2026. Chairman Tony Ho said the funds will let the company "capitalise on the significant opportunities we have in the year ahead." Entitlements and shortfall shares are due to be allotted on 30 June 2026.
What could go wrong? Not all the demand can be filled yet. Directors plan to seek shareholder approval at a general meeting around 28 July 2026 before allocating 22,188,094 shares applied for beyond the offer. The low share price also reflects a small-cap company still working to scale commercially.
The signal: The rights issue closing 15% oversubscribed — pushing the combined placement and rights raise past NZ$4 million — points to investor appetite for diagnostics that promise cheaper, faster cervical cancer screening in underserved markets. With TruScreen Ultra certified across Australia, the UK, China, Russia, Saudi Arabia and Mexico and distributors in 29 countries, shareholders appear to be betting the company can finally convert that global footprint into revenue.
Read more: ListCorp
